Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

B7688

Sigma-Aldrich

PiB

≥98% (HPLC)

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
RM 406.00
25 MG
RM 1,625.00

RM 406.00

Estimated to ship on24 May 2025

Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
RM 406.00
25 MG
RM 1,625.00

About This Item

Empirical Formula (Hill Notation):
C22H18N2O8
CAS Number:
64005-90-9
Molecular Weight:
438.39
MDL number:
MFCD00333607
UNSPSC Code:
12352200
PubChem Substance ID:
329773301
NACRES:
NA.77

RM 406.00

Estimated to ship on24 May 2025

Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to light brown

solubility

DMSO: 1-2 mg/mL (warmed)

storage temp.

2-8°C

SMILES string

O=C(C1=C2C(C3=CC=C24)=C(C(N(CC(OCC)=O)C3=O)=O)C=C1)N(CC(OCC)=O)C4=O

InChI

1S/C22H18N2O8/c1-3-31-15(25)9-23-19(27)11-5-7-13-18-14(8-6-12(17(11)18)20(23)28)22(30)24(21(13)29)10-16(26)32-4-2/h5-8H,3-4,9-10H2,1-2H3

InChI key

WNKQGFNIIHNGQM-UHFFFAOYSA-N

Biochem/physiol Actions

PiB is a Pin-1 inhibitor.
PiB is an inhibitor of the peptidylprolyl isomerase Pin-1. Inhibition of Pin-1 leads to destabilization of the transcription factor Nanog, which is required for maintenance of embryonic stem cell cultures.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
123M4603V
120M4621V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Bernard J Hanseeuw et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 14(10), 1281-1292 (2018-05-25)
Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical;
Stephan Müller et al.
Scientific reports, 7(1), 1225-1225 (2017-04-30)
The relationship between body-mass index (BMI) and Alzheimer´s disease (AD) has been extensively investigated. However, BMI alterations in preclinical individuals with autosomal dominant AD (ADAD) have not yet been investigated. We analyzed cross-sectional data from 230 asymptomatic members of families
Christopher M Lee et al.
Journal of Alzheimer's disease : JAD, 62(4), 1691-1702 (2018-04-05)
On target 18F-Flortaucipir (FTP) binding of Alzheimer's disease tau aggregates and off-target binding of melanocytes have been demonstrated with autoradiography. We aimed to investigate the hypothesis that if binding in choroid plexus (CP) is due to melanocytes, the signal would
Inge M W Verberk et al.
Alzheimer's research & therapy, 12(1), 118-118 (2020-09-30)
Blood-based biomarkers for Alzheimer's disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta(1-42/1-40), glial fibrillary acidic protein (GFAP) and neurofilament light
Lisa Vermunt et al.
Neurology, 92(23), e2699-e2705 (2019-05-10)
To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative.
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service